- Home
- WWR vs ANVS Comparison
WWR vs ANVS Comparison
Compare WWR & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWR | ANVS |
|---|---|---|
| Founded | 1977 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.3M | 69.1M |
| IPO Year | 2006 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WWR | ANVS |
|---|---|---|
| Price | $0.51 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $1.92 | ★ $13.50 |
| AVG Volume (30 Days) | 936.5K | ★ 1.1M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $1.54 |
| 52 Week High | $3.75 | $5.50 |
Technical Indicators
Market Signals| Indicator | WWR | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 41.30 |
| Support Level | $0.47 | $1.73 |
| Resistance Level | $0.72 | $2.34 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 28.58 | 13.70 |
Price Performance
Historical ComparisonAbout WWR Westwater Resources Inc.
Westwater Resources Inc is an energy technology company focused on developing battery-grade natural graphite materials through a vertically integrated, mine-to-market strategy anchored by its two primary projects in Coosa County, Alabama: the Kellyton Graphite Plant and the Coosa Graphite Deposit. Westwater also holds mineral rights to explore and mine the Coosa Graphite Deposit, which Westwater anticipates will eventually provide natural graphite flake concentrate as feedstock to the Kellyton Graphite Plant.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.